5-[2-(4-Fluorophenyl)pyridin-4-yl]-4-pyridin-2-yl-1,3-thiazol-2-amine | 446301-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-[2-(4-Fluorophenyl)pyridin-4-yl]-4-pyridin-2-yl-1,3-thiazol-2-amine
• CAS: 446301-82-2
• 化学式: C₁₉H₁₃FN₄S
• 分子量: 348.403
• InChiKey: SDIXYNIQJJQJSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Compounds
  申请人：Dodic Nerina

  公开号：US20060004051A1

  公开（公告）日：2006-01-05

  The invention relates to novel aminothiazole derivatives which are inhibitors of the transforming growth factor, (“TGF”)-β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

  本发明涉及一种新型的氨基噻唑衍生物，该衍生物是转化生长因子（“TGF”）-β信号通路的抑制剂，特别是抑制TGF-β类型I或类激活素样激酶（“ALK”）-5受体对smad2或smad3的磷酸化，以及该衍生物的制备方法和在医学上的应用，具体地用于治疗和预防由该通路介导的疾病状态。
• Thiazolmines and their use as tgf-beta inhibitors
  申请人：——

  公开号：US20040077687A1

  公开（公告）日：2004-04-22

  Therapeutically active thiazole derivatives of formula (I) wherein R 1 and R 2 are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor &bgr; (TGF-&bgr;), and pharmaceutical compositions for use in such therapy. 1

  具有治疗活性的式(I)噻唑衍生物 其中 R 1 和 R 2 如说明书中所定义，其制备工艺，其在治疗中的用途，特别是在治疗或预防以转化生长因子&bgr;（TGF-&bgr;）过度表达为特征的疾病中的用途，以及用于此类治疗的药物组合物。 1
• THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1355870A1

  公开（公告）日：2003-10-29
• COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1554275A2

  公开（公告）日：2005-07-20
• EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS
  申请人：Ichida Justin

  公开号：US20120021519A1

  公开（公告）日：2012-01-26

  The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.